Better Therapeutics (BTTX) Competitors

Better Therapeutics logo
$0.0001 0.00 (0.00%)
As of 11/12/2026

BTTX vs. UPHL, BPTH, NVOS, VRAYQ, and VSEE

Should you buy Better Therapeutics stock or one of its competitors? Better Therapeutics's main competitors and comparable companies include UpHealth (UPHL), Bio-Path (BPTH), Novo Integrated Sciences (NVOS), ViewRay (VRAYQ), and VSee Health (VSEE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Better Therapeutics compare to UpHealth?

Better Therapeutics (NASDAQ:BTTX) and UpHealth (NYSE:UPHL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Better Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, UpHealth has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Better Therapeutics has higher earnings, but lower revenue than UpHealth. Better Therapeutics is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.15N/A
UpHealth$130M0.00-$56.42M$2.38N/A

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
UpHealth N/A N/A N/A

In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled UpHealth'saverage media sentiment score.

Company Overall Sentiment
Better Therapeutics Neutral
UpHealth Neutral

34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 56.1% of UpHealth shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 34.2% of UpHealth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

UpHealth beats Better Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Better Therapeutics compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and Better Therapeutics (NASDAQ:BTTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Better Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.09N/A
Better TherapeuticsN/AN/A-$39.76M-$0.15N/A

Bio-Path has a beta of -0.8, suggesting that its share price is 180% less volatile than the broader market. Comparatively, Better Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 51.4% of Better Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Better Therapeutics' return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
Better Therapeutics N/A N/A N/A

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
Better Therapeutics Neutral

Summary

Better Therapeutics beats Bio-Path on 6 of the 8 factors compared between the two stocks.

How does Better Therapeutics compare to Novo Integrated Sciences?

Better Therapeutics (NASDAQ:BTTX) and Novo Integrated Sciences (NASDAQ:NVOS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled Novo Integrated Sciences'average media sentiment score.

Company Overall Sentiment
Better Therapeutics Neutral
Novo Integrated Sciences Neutral

Novo Integrated Sciences has higher revenue and earnings than Better Therapeutics. Novo Integrated Sciences is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.15N/A
Novo Integrated Sciences$13.52M0.00-$16.17M-$0.87N/A

Better Therapeutics has a net margin of 0.00% compared to Novo Integrated Sciences' net margin of -121.55%. Better Therapeutics' return on equity of 0.00% beat Novo Integrated Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
Novo Integrated Sciences -121.55%-93.07%-46.28%

34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Novo Integrated Sciences shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by insiders. Comparatively, 10.4% of Novo Integrated Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Better Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Novo Integrated Sciences has a beta of 5.33, suggesting that its share price is 433% more volatile than the broader market.

Summary

Better Therapeutics beats Novo Integrated Sciences on 7 of the 10 factors compared between the two stocks.

How does Better Therapeutics compare to ViewRay?

ViewRay (NASDAQ:VRAYQ) and Better Therapeutics (NASDAQ:BTTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
Better Therapeutics N/A N/A N/A

ViewRay has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Better Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

15.5% of ViewRay shares are owned by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are owned by institutional investors. 2.5% of ViewRay shares are owned by company insiders. Comparatively, 51.4% of Better Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, ViewRay's average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score.

Company Overall Sentiment
ViewRay Neutral
Better Therapeutics Neutral

Better Therapeutics has lower revenue, but higher earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33MN/AN/A
Better TherapeuticsN/AN/A-$39.76M-$0.15N/A

Summary

Better Therapeutics beats ViewRay on 4 of the 6 factors compared between the two stocks.

How does Better Therapeutics compare to VSee Health?

VSee Health (NASDAQ:VSEE) and Better Therapeutics (NASDAQ:BTTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Better Therapeutics has a net margin of 0.00% compared to VSee Health's net margin of -92.36%. Better Therapeutics' return on equity of 0.00% beat VSee Health's return on equity.

Company Net Margins Return on Equity Return on Assets
VSee Health-92.36% -11,636.34% -68.62%
Better Therapeutics N/A N/A N/A

VSee Health has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Better Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VSee Health
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Better Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, VSee Health had 2 more articles in the media than Better Therapeutics. MarketBeat recorded 2 mentions for VSee Health and 0 mentions for Better Therapeutics. Better Therapeutics' average media sentiment score of 0.00 beat VSee Health's score of -0.36 indicating that Better Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
VSee Health Neutral
Better Therapeutics Neutral

1.0% of VSee Health shares are held by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are held by institutional investors. 14.9% of VSee Health shares are held by insiders. Comparatively, 51.4% of Better Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

VSee Health has higher revenue and earnings than Better Therapeutics. VSee Health is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VSee Health$14.46M0.00-$14.71M-$31.88N/A
Better TherapeuticsN/AN/A-$39.76M-$0.15N/A

Summary

Better Therapeutics beats VSee Health on 9 of the 13 factors compared between the two stocks.

Get Better Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BTTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

BTTX vs. The Competition

MetricBetter TherapeuticsHealth services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4K$16.43M$7.43B$10.86B
Dividend YieldN/AN/A2.51%4.77%
P/E Ratio0.00N/A32.5628.75
Price / SalesN/AN/A8.105.41
Price / CashN/AN/A20.2520.77
Price / BookN/AN/A4.343.51
Net Income-$39.76M-$39.76M$3.51B$394.12M
7 Day PerformanceN/AN/A-8.07%-8.97%
1 Month PerformanceN/AN/A-10.29%-11.61%
1 Year PerformanceN/AN/A-4.70%-11.21%

Better Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BTTX
Better Therapeutics
N/A$0.00
flat
N/AN/A$4KN/AN/A54
UPHL
UpHealth
N/A$0.00
flat
N/AN/A$2K$130MN/A374
BPTH
Bio-Path
N/A$0.00
flat
N/A-99.6%$16KN/AN/A10
NVOS
Novo Integrated Sciences
N/A$0.00
+33.3%
N/A-56.0%$16K$13.52MN/A170
VRAYQ
ViewRay
N/AN/AN/AN/A$16K$102.21MN/A300

Related Companies and Tools


This page (NASDAQ:BTTX) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners